Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mass Spec Predicts Improved Response to Anti-HER2 Therapy in Breast Cancer

Published: Monday, July 07, 2014
Last Updated: Monday, July 07, 2014
Bookmark and Share
Immunohistochemistry is the standard technique for detecting HER2 protein expression, it does not provide absolute quantification of this receptor and is prone to false-positives.

A collaborative study between OncoPlex Diagnostics, Vall d´Hebron Institute of Oncology (VHIO), and Memorial Sloan Kettering Cancer Center, with support from the BBVA Foundation, defined for the first time a quantitative HER2 protein level measured by mass spectrometry is associated with longer disease free and overall survival in patients receiving anti-HER2 treatment.   Results of the study were presented during the ASCO 2014 Annual Meeting by Dr. Paolo Nuciforo, Principal Investigator of VHIO´s Molecular Oncology Group. 

While immunohistochemistry (IHC) is the standard technique for detecting HER2 protein expression, it does not provide absolute quantification of this receptor and is prone to false-positives. Many patients who are classified by IHC as HER2-positive actually express low levels of the receptor which dramatically reduces efficacy of anti-HER2 therapy. 

OncoPlex Diagnostics uses the patented Liquid Tissue® process to solubilize formalin-fixed, paraffin-embedded (FFPE) tissue for precise protein quantitation by mass spectrometry analysis.  The study analyzed tissue from 60 breast cancer patients previously classified as IHC 3+ and treated with anti-HER2 therapy.  The research revealed high variability in HER2 expression within the patient population that had been homogenously classified as 3+ by IHC. Patients with HER2 protein levels greater than or equal to 2758.75 amol/ug, as measured by mass spectrometry, correlated with greater clinical benefit including prolonged survival rates.  The ASCO poster presentation is available at OncoPlex Dx HER2 ASCO2014 Collaboration.

"This study provides evidence that quantitative measurement by mass spectrometry of a tumor-driving protein such as HER2 correlates with the clinical benefit associated with HER2 targeted therapy," stated Dr. Jedd Levine, Chief Medical Officer for OncoPlex Diagnostics. The primary investigator, Dr. Nucifiro, explains, "If future (ongoing) studies enrolling a greater number of patients confirm these results, this would represent an important game-changer in how we currently determine HER2 expression levels as well as provide oncologists with further insight to better tailor anti-HER2-based therapies according to HER2 protein levels."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Coding and Computers Help Spot Methane, Explosives
Coded apertures improve and shrink mass spectrometers for field use.
Why Bearcats Smell Like Buttered Popcorn
Researchers pinpoint chemical compound that gives rare animal its popcorn-like scent.
UCSD Scientists Receive NIH Grant to Combat Antibiotic Resistance
Interdisciplinary program will use systems biology approaches to understand how antibiotics work in concert with patient’s immune system.
Virus Causing Tilapia Die-Offs Identified
Discovery of the virus causing Tilapia die-offs in Israel and Ecuador points the way to protecting a fish that feeds multitudes.
Novel Collagen Fingerprinting Identifies A Neanderthal
Study from the universities of Oxford and Manchester uses ZooMS technique to identify traces of an extinct human.
Hope for Combating Muscular Dystrophy
Decoding a sugar molecule and identifying a mechanism linking it to MS could help in the development of therapy for the disease.
Decoding Sugar Molecules Offers New Key For Combating Muscular Dystrophy
Japanese scientists find a rare sugar unit called ribitol 5-phosphate within the sugar molecules on the surface of muscle cells. Mutations in 3 genes linked to muscular dystrophy affect the creation of this sugar molecule.
A Vision for Precision Medicine
The University of Manchester and the University of Dundee partner to share disease screening data.
New Targets for Diabetes, Inflammation Discovered
The Scripps Research Institute and Salk Scientists discover 'outlier' enzymes that could offer new targets to treat diabetes and inflammation.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!